Dr. Martens (LON:DOCS) Insider Ije Nwokori Acquires 192 Shares

Dr. Martens plc (LON:DOCS) insider Ije Nwokori bought 192 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was purchased at an average price of GBX 78 per share, with a total value of £149.76.

Ije Nwokori also recently made the following trade(s):

• On Thursday, December 11th, Ije Nwokori purchased 197 shares of Dr. Martens stock. The shares were purchased at an average cost of GBX 76 per share, for a total transaction of £149.72.
• On Tuesday, November 11th, Ije Nwokori acquired 176 shares of Dr. Martens stock. The stock was purchased at an average price of GBX 85 per share, for a total transaction of £149.60.

Dr. Martens Stock Performance

LON:DOCS opened at GBX 75.95 on Friday. The firm has a 50-day moving average of GBX 77.89 and a two-hundred day moving average of GBX 83.45. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13. The stock has a market cap of £734.10 million, a P/E ratio of 44.68, a PEG ratio of 6.40 and a beta of 0.11. Dr. Martens plc has a 1-year low of GBX 43.02 and a 1-year high of GBX 100.87.

Dr. Martens (LON:DOCS) last released its quarterly earnings results on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, research analysts expect that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on DOCS shares. Peel Hunt reiterated a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 20th. Berenberg Bank reaffirmed a “buy” rating on shares of Dr. Martens in a report on Thursday, November 27th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of GBX 6,000.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.